IL-21和Tfh细胞介导NSCLC免疫治疗的研究进展  

Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer

作　　者：刘兴锴 张一帆 张鑫 何功浩 蔡文科 Xingkai LIU;Yifan ZHANG;Xin ZHANG;Gonghao HE;Wenke CAI(Department of Cardiothoracic Surgery,920th Hospital of Joint Logistic Support Force of the People's Liberation Army,Kunming 650032,China;Kunming Medical University,Kunming 650500,China;Department of Respiratory and Critical Care Medicine,920th Hospital of Joint Logistic Support Force of the People's Liberation Army,Kunming 650032,China;Department of Clinical Pharmacy,920th Hospital of Joint Logistic Support Force of the People's Liberation Army,Kunming 650032,China)

机构地区：[1]中国人民解放军联勤保障部队第九二〇医院胸心外科,昆明650032 [2]昆明医科大学,昆明650500 [3]中国人民解放军联勤保障部队第九二〇医院呼吸与危重症医学科,昆明650032 [4]中国人民解放军联勤保障部队第九二〇医院临床药学科,昆明650032

出　　处：《中国肺癌杂志》2024年第7期550-558,共9页Chinese Journal of Lung Cancer

基　　金：云南省中青年学术和技术带头人后备人才项目(No.2019HB045和No.202405AC350037)资助。

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)作为全球范围内频发且极具侵袭性的癌症之一,传统的手术治疗、放化疗及靶向治疗等方法往往由于其固有的局限性,难以遏制病情的进展,导致预后效果并不理想。尽管近年来免疫治疗药物的出现为NSCLC治疗带来了新希望,显示出一定的治疗效果,但当前的疗效仍显不足,无法满足所有患者的治疗需求。因此积极探索新的免疫治疗手段来进一步降低患者的死亡率,已成为NSCLC研究领域的重要方向。本文旨在通过梳理和分析国内外相关文献,系统综述白细胞介素21(interleukin-21,IL-21)和滤泡辅助性T细胞(follicular helper T cells,Tfh)在NSCLC免疫治疗中的抗肿瘤作用,并探讨通过免疫治疗手段调控免疫检查点,以改善NSCLC治疗前景的可能性。Non-small cell lung cancer(NSCLC)is a prevalent and aggressive global malignancy.Conventional sur-gical treatments,radiotherapy,chemotherapy,and targeted therapies often fall short in halting disease progression due to inher-ent limitations,resulting in suboptimal prognosis.Despite the advent of immunotherapy drugs offering new hope for NSCLC treatment,current efficacy remains insufficient to meet all patient needs.Therefore,actively exploring novel immunotherapeu-tic approaches to further reduce mortality rates in NSCLC patients has become a crucial focus of NSCLC research.This article aims to systematically review the anti-tumor effects of interleukin-21 and follicular helper T cells in NSCLC immunotherapy by summarizing and analyzing relevant literatures from both domestic and international sources,as well as exploring the potential for enhancing NSCLC treatment prospects through immune checkpoint regulation via immunotherapeutic means.

关 键 词：肺肿瘤 滤泡辅助性T细胞 白细胞介素21 免疫检查点蛋白 

分 类 号：R734.2[医药卫生—肿瘤]